Wockhardt Pharma Share Price: Wockhardt Limited is one of India’s major pharmaceutical companies, specializing in biopharmaceuticals, vaccines, and generic medicines.
Wockhardt holds a significant market position in both emerging and developed markets, capitalizing on the rising global demand for healthcare services and pharmaceuticals. The company has also invested heavily in R&D activities, operating eight FDA-approved units across the U.S., U.K., and India.
This analysis provides a comprehensive projection of Wockhardt’s share price targets from 2024 to 2030, including its financial indicators, ownership trends, and drivers for industry growth.
Wockhardt Pharma Company Overview
| Company Name | Wockhardt Pharma Ltd. |
| Founded | 1960s |
| Headquarters | Mumbai |
| Industry | Pharmaceuticals, Health care |
| Chairman | Habil Khorakiwala |
| Stock Exchange Listing | NSE & BSE |
| Official Website | wockhardt.com |
Wockhardt Pharma Fundamental Analysis
| Metric | Value |
|---|---|
| Market Cap | ₹24,827.40 Cr. |
| ROE | -23.98% |
| ROCE | -5.32% |
| P/E | 0 |
| P/B | 8.98 |
| Div. Yield | 0% |
| Book Value | ₹170.17 |
| Face Value | ₹5 |
| EPS (TTM) | ₹-14.16 |
| 52 Week High | ₹1,467 |
| 52 Week Low | ₹376.50 |
Also Read: Praj Industries Share Price Target
Wockhardt Pharma Financials
Income Statement
| (INR) | 2024 | Y/Y change |
|---|---|---|
| Revenue | 28.30B | 6.51% |
| Operating expense | 16.19B | -0.55% |
| Net income | -4.63B | 17.17% |
| Net profit margin | -16.36 | 22.24% |
| Earnings per share | — | — |
| EBITDA | 1.39B | 230.95% |
| Effective tax rate | -12.38% | — |
Balance Sheet
| (INR) | 2024 | Y/Y change |
|---|---|---|
| Cash and short-term investments | 5.23B | 350.86% |
| Total assets | 76.49B | -0.44% |
| Total liabilities | 39.87B | -0.85% |
| Total equity | 36.62B | — |
| Shares outstanding | 153.40M | — |
| Price to book | 6.51 | — |
| Return on assets | -0.17% | — |
| Return on capital | -0.22% | — |
Cash Flow
| (INR) | 2024 | Y/Y change |
|---|---|---|
| Net income | -4.63B | 17.17% |
| Cash from operations | 2.19B | 43.14% |
| Cash from investing | -1.37B | -9.60% |
| Cash from financing | 3.34B | 206.03% |
| Net change in cash | 4.15B | 248.21% |
| Free cash flow | 390.00M | 188.89% |
Also Read: Ceigall India Ltd Share Price Target
Wockhardt Pharma Share Price Target From 2024 to 2030
| Year | Target Price |
|---|---|
| Wockhardt Pharma Share Price Target 2024 | ₹1610 |
| Wockhardt Pharma Share Price Target 2025 | ₹2550 |
| Wockhardt Pharma Share Price Target 2026 | ₹3672 |
| Wockhardt Pharma Share Price Target 2027 | ₹4868 |
| Wockhardt Pharma Share Price Target 2028 | ₹5995 |
| Wockhardt Pharma Share Price Target 2029 | ₹7230 |
| Wockhardt Pharma Share Price Target 2030 | ₹8351 |
Wockhardt Pharma Shareholding Pattern
- Retail & Other: 34.41%
- Promoters: 49.09%
- Foreign Institutions: 6.62%
- Mutual Funds: 7.09%
- Other Domestic Institutions: 2.79%
Also Read: Sky Gold Share Price Target
Wockhardt Pharma Competitors/Peer Companies
- Piramal Pharma
- Suven Pharma
- Laurus Labs
- JBCPL
- Natco Pharma
- Emcure Pharma
- Concord Biotech
- Granules India
- Glenmark Life
- Akums Drugs & Pharmaceuticals
Also Read: Cochin Shipyard Share Price Target
To connect with us, click on any of the given social media buttons.
FAQs
-
What is the Wockhardt Pharma Ltd Share Price Prediction 2025?
By 2025, Wockhardt’s stock is expected to rise up to 2,550 INR significantly. This growth will be driven by new product launches, particularly in emerging markets.
Additionally, the company’s focus on vaccine and biosimilar developments is likely to increase international market interest, further boosting the stock. -
What is the Wockhardt Pharma Ltd Share Price Prediction 2026?
The estimated share price for Wockhardt in 2026 is around 3,672 INR. This growth will be sustained by the increasing demand for biopharmaceuticals.
The company will further strengthen its global market position through investments in research facilities and technology in the U.S. and Europe, making Wockhardt a suitable choice for institutional investors seeking long-term growth. -
What is the Wockhardt Pharma Ltd Share Price Prediction 2027?
In 2027, Wockhardt’s stock price is likely to reach 4,868 INR due to robust product launches and expanded market penetration. The company’s strong focus on the biosimilar business, which is expected to generate higher revenues, will lead to improved profitability.
-
What is the Wockhardt Pharma Ltd Share Price Prediction 2029?
By 2029, the share price is projected to rise to 7,230 INR. This increase will be driven by the company’s continued expansion into high-demand areas such as biosimilars and generics.
Strengthening its market share in Europe through strategic buyouts and launches will solidify Wockhardt’s position within the pharmaceutical industry. -
What is the Wockhardt Pharma Ltd Share Price Prediction 2030?
In 2030, Wockhardt’s share price may touch 8,351 INR. This projection is based on the company’s growth in both emerging and developed markets, high-margin products, and revenue generation from biosimilars and innovative medicines.
Wockhardt’s stock offers potential for handsome returns for long-term investors as the company consolidates its position as a leader in the pharmaceutical industry.
Disclaimer: The information in this blog is for educational purposes only, and the targets mentioned in it are given as suggestions by market analysts. Therefore, before investing your money in any company, it is mandatory to get complete information about the company and consult your financial advisor.
